An evergreen life science venture fund located in Europe established 2009 and wholly owned by a Philanthropic Foundation is seeking new investments. The fund’s evergreen structure allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. The fund has an annual investment capacity of approximately €50m. Investments are typically above €10-35m, and the firm prefers to take above 10% ownership. The fund invests primarily in Europe and in the USA/Canada.

The fund invests exclusively in life sciences, focusing on pharmaceuticals and medtech. For therapeutics, the firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The fund will consider investing in medtech companies at the commercialization stage. The firm is open to opportunities in all therapeutic areas and indications.

The fund is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US/Canada the firm prefers to syndicate with well-established VC investors specialized in life sciences. The fund expects to be actively in communication with management and represented on the supervisory board of portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

​A Venture Capital fund formed by a partnership between a European pharmaceutical company and US based venture capital firm is currently looking to make seed and venture stage investments into life science companies ranging anywhere from $200K to $5 million initially and up to $8 million over the life of the investment. The fund is actively seeking investment opportunities throughout the United States and Europe and could make as many as 2-4 new investments over the next year.

​The fund is focused on rare and orphan diseases that affect less than 200,000 people throughout the United States. Within this area the fund is open to therapeutics and diagnostics across a number of technology types including, antibodies, small molecules, stem cells, cell therapy, gene therapy, vaccines, molecular diagnostics, and genomics among others. The fund is interested in companies anywhere from pre-clinical through phase III of clinical trials and has no preference for platform or single asset companies. The fund is not interested in biosimilars or generics.

​The fund is looking for privately held companies with experienced management teams. The fund looks to act as a hands on investor and seeks board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office/venture capital firm based in New York firm manages an evergreen fund that seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm based in the Eastern US that has managed two venture capital funds in the past, is currently making angel investments from the founders private funds. These investments are typically $1-3m, but are highly varied and may be higher. The firm is focused on investing in US-based companies.

The firm invests in a range of industries, and within the life science sector the firm is focused on investing in medical devices. The firm will consider opportunities in any areas of medical technology and in any indication area, but is particularly interested in products that present an easier regulatory route and a quicker time to market. The firm prefers to invest in products that have already entered clinical trials. The firm does not invest in instrumentation/lab equipment.

The firm does not have any specific requirements for companies and management teams, but generally only invests in pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

​A venture capital company with office on the east and west coasts of the United States is currently making investments out of its 1st $180 million fund and is capable of making investments ranging from $5-$20 million into selected companies. The firm has made both equity and convertible note investments and is looking to make 3-6 investments over the next 6-9 months. The firm is looking for companies located globally.

The firm is looking to invest in the Therapeutics space and is open to considering both small molecules and biologics. The firm is looking for companies in the clinical stage that are at least post proof of concept. The firm is generally open to all subsectors and indications including orphan diseases.

​The firm is looking for management teams with experience that are backed d by strong science and a solid strategy. The firm looks to act as a hands on investor generally taking a board seat following investment. The firm is open to investing in both private and publically held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The Corporate Venture Capital Arm of large pharma company is currently investing from its second fund of $100M. The firm invests in early-stage biotechnology companies focusing on discovering and developing human therapeutics primarily in the areas of the current therapeutic interest to the firm’s parent company. The firm typically invests (equity) $3-$4M per round with $10M reserved for follow-on investments. The firm seeks companies that are based in the US and Europe. The firm seeks to make about 2-3 allocations in the next 6-9 months.

The firm seeks early-stage companies developing human therapeutics. The firm is seeking companies with products in pre-clinical to phase IIa. The firm’s therapeutic areas of focus are: Cardiovascular (Acute Coronary Syndromes, Dyslipidemia, Heart Failure); Hematology (Anemia, Neutropenia, Stem Cell Mobilization); Inflammation (Asthma, Bowel Disease, Multiple Sclerosis, Osteoarthritis, Psoriasis, Rheumatoid arthritis, Systemic Lupus Erythematosus); Metabolic Disorders (Diabetes, Osteoporosis); Nephrology (Hyperparathyroidism, Renal Failure); Neuroscience (Alzheimer’s Disease, Cognition, Pain-Neuropathic & Inflammatory, Parkinson’s Disease, Schizophrenia); and Oncology. The firm is also interested in drug delivery therapeutics and Healthcare IT

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An innovative global private equity firm utilizing a virtual pharma (asset centric) model is looking to invest in early stage pharmaceutical assets, and is capable of providing $15-$20 million or more to get a project through proof of concept. The firm prefers to acquire or in-license individual pharmaceutical assets and is much less likely to make traditional equity investments into companies. Ideal candidates have yet to receive significant VC funding and the firm prefers to invest without syndicates. The firm in interested in investing in projects around the globe and is capable of making 15+ investments over the course of the next year if enough high quality investments present themselves.

The firm is looking primarily for pharmaceutical assets and to a much lesser extent diagnostics and medical devices. The firm is willing to invest in assets that are as far as 12-18 months pre-IND to those that are early in phase I of clinical trials and ideal candidates are IND ready and preparing to enter phase I. The firm is open to all indications where proof of concept can be shown in early clinical trials which generally excludes assets targeting a number of CNS disorders. For medical device and diagnostic opportunities only very select programs of extreme appeal will be considered.

The firm is looking to partner with management teams that have an extreme understanding of the science behind their product and that are willing to operate in a virtual environment. The firm acts as an extremely hands on investor often integrating investments into the parent company and ensuring that all assets are developed in the most effective and risk-diversified manner.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com